CA2874555A1 - Synthesis of pyrrolo [2, 3 - b] pyridines - Google Patents

Synthesis of pyrrolo [2, 3 - b] pyridines Download PDF

Info

Publication number
CA2874555A1
CA2874555A1 CA2874555A CA2874555A CA2874555A1 CA 2874555 A1 CA2874555 A1 CA 2874555A1 CA 2874555 A CA2874555 A CA 2874555A CA 2874555 A CA2874555 A CA 2874555A CA 2874555 A1 CA2874555 A1 CA 2874555A1
Authority
CA
Canada
Prior art keywords
compound
formula
optionally substituted
aryl
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2874555A
Other languages
French (fr)
Other versions
CA2874555C (en
Inventor
Prabha N. Ibrahim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2874555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of CA2874555A1 publication Critical patent/CA2874555A1/en
Application granted granted Critical
Publication of CA2874555C publication Critical patent/CA2874555C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Abstract

Provided herein are intermediates and processes useful for facile synthesis of biologically active molecules. The intermediates are compounds of formula (I):
(see formula I)

Description

SYNTHESIS OF PYRROLO [2, 3 - 13] PYRIDINES
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. 119(e) of United States Provisional Application No. 61/653,994, filed on May 31, 2012, which is incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to heterocyclic compounds, methods for the preparation thereof, and compounds prepared employing same.
BACKGROUND OF THE INVENTION
[0003] N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoro-phenyl]propane-1-sulfonamide or propane-l-sulfonic acid {3-[5-( 4-chloro-phenyl )-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl} -amide (Vemurafenib;
Zelborafrm) is effective for the treatment of various B-raf mediated diseases and conditions, including, but not limited to, metastatic melanoma, thyroid cancers and colorectal cancers (Nature, 2010, 467, 596-599; New England Journal of Medicine, 2010, 363, 80). The compound and its synthesis have been described in PCT Patent Publication Nos. WO 2007/002433 and WO
2007/002325. There remains interest in developing other versatile and facile processes for the efficient preparation of this and other biologically active molecules, especially, on an industrial scale.
SUMMARY OF THE INVENTION
[0004] In one aspect, the present invention provides a compound of formula (I):
Q
0 .

I \ F
N N, p2 (I) The compound can be used as an intermediate for the synthesis of various biologically active molecules. In formula (I):
5 PCT/US2013/043400 Q is F or H;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group or hydrogen; and L1 is Br, Cl, I, R1-S020- or R2C(0)0; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl.
In one embodiment, P1 is H. In another embodiment, Q is F; P1 is H; and L1 is Br.
[0005] In another aspect, the present invention provides a method for preparing a compound of formula (I). The method comprises contacting a compound of formula (II):
Q
0 .

i =-=., \ F NH2 I
N N
H (II) with an agent having the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
Q
0 e i =-,... \ F NH2 I
N N
iD2 (Ia);
and contacting a compound of formula (Ia) with an agent of formula: P1-X3 under conditions sufficient to form the compound of formula (I),wherein:
X1 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-;
X3 is a leaving group;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group;
Q is H or F; and L1 is Br, Cl, I, R1-S020- or R2C(0)0; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl.
[0006] In yet another aspect, the present invention provides a method for preparing a compound of formula (III):

Q
0 =//0 Y
1 \ \ F H N1\

N N
H (III).
The method comprises (i) contacting a compound of formula (I) with an agent having the formula : Y-B(0R5)2 (i.e., formula IVb) or the formula : Y-Sn(Bu)3 (i.e., formula IVc) and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IV):
Q
0 41k, Y
\ F NHP1 I
N N
\
p2 (IV), (ii) reacting a compound of formula (IV) with an agent of the formula : A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (IX);
Q
0 41k, Y 1 \ F HN-/\

N N
\
p2 (IX), and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III), wherein:
Q is H or F;
R5 is ¨OH, Ci_6alkyl or two ¨0R5 substituents together with the boron atom to which they are attached form an optionally substituted 5 or 6-membered ring;
A1 is a leaving group;
Y is optionally substituted aryl or optionally substituted heteroaryl; and Z is ¨N(R6)(R7) or ¨C(R8)(R9)(R10); wherein:
R6 and R7 are each independently selected from the group consisting of H, optionally substituted Ci_6alkyl, optionally substituted C3_8cycloalkyl, optionally substituted C3_8cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, 0 or S, wherein the four to eight-membered ring is optionally substituted; and R8, R9 and R1 are each independently H, optionally substituted Ci_6alkyl, optionally substituted, Ci_6haloalkyl, optionally substituted Ci_6haloalkoxy, optionally substituted C3_8cycloalkyl, optionally substituted C3_ 8cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or -X2R11, wherein X2 is -NR12, 0 or S; R12 is H, Ci_6alkyl or aryl; and R11 is H, Ci_6alkyl, Ci_6haloalkyl, Ci_6haloalkoxy, C3_8cycloalkyl, C3_ 8cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R11 is optionally substituted with from 1 to 3 Re substituents selected from halogen, -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Rf, -SRf, -0C(0)R, -0C(S)R, -C(0)R, -C(S)R, -C(0)OR, -C(S)OR, -S(0)R, -S(0)2R, -C(0)NHRf, -C(S)NHRf, -C(0)NRfRf, -C(S)NRfRf, -S(0)2NHRf, -S(0)2NRfRf, -C(NH)NHRf, -C(NH)NRfRf, -NHC(0)Rf, -NHC(S)Rf, -NRfC(0)Rf, -NRfC(S)Rf, -NHS(0)2R, -NRfS(0)2Rf, -NHC(0)NHRf, -NHC(S)NHRf, -NRfC(0)NH2, -NRfC(S)NH2, -NRfC(0)NHRf, -NRfC(S)NHRf, -NHC(0)NRfRf, -NHC(S)NRfRf, -NRfC(0)NRfRf, -NRfC(S)NRfRf, -NHS(0)2NHRf, -NRfS(0)2NH2, -NRfS(0)2NHRf, -NHS(0)2NRfRf, -NRfS(0)2NRfRf , -NHRf, -NRfRf and Rf, wherein Rf is Ci-6alkyl, C3_6cycloalkyl, heterocycloalkyl, heteroaryl or aryl, wherein Rf is optionally substituted with from 1-3 Rg substituents selected from -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR", -SR", -0C(0)Rh, -0C(S)Rh, -C(0)Rh, -C(S)R", -C(0)OR", -C(S)OR", -S(0)Rh, -S(0)2R", -C(0)NHRh or Rh, wherein Rh is Ci_6alkyl; or any two of the R8, R9 and R1 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, 0 or S.
DETAILED DESCRIPTION OF THE INVENTION
[0007] The present invention is related to novel synthetic intermediates and processes for the large-scale preparation of compounds that have the following core structure (aa):
/ 5 0 et I I
F
NH-S-I I I

N
(aa), namely, [2,6-difluoro-3-(sulfonylamino)pheny1]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone core or [2-fluoro-3-(sulfonylamino)pheny1]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone core.
The wavy lines indicate the points of attachment to the remainder of the structure. In some embodiments, the 5-position of the 7-azaindole ring in the core structure (aa) is occupied with the substituent Y and the sulfonyl group is linked to the substituent Z. The variables Q, Y
and Z are as defined in the Summary of the Invention and any of the embodiments as described herein. For example, the present invention provides synthetic methods and intermediates useful for the large scale preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoro-phenyl]propane-1-sulfonamides or propane-1-sulfonic acid {3-[5-( 4-chloro-phenyl )-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl} -amides. Advantageously, the present invention provides synthetic intermediates and versatile processes, which allow for high efficiency, low cost and large-scale facile synthesis of biologically active molecules including vemurafenib with high purity. The intermediates of the present invention can be readily adapted to the facile preparation of various compounds having core structure (aa).
Definitions
[0008] It is noted here that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.
[0009] "Halogen" or "halo" refers to all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), or iodo (I).
[0010] "Hydroxyl" or "hydroxy" refers to the group -OH.
[0011] "Thiol" refers to the group -SH.
[0012] The term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon, having the number of carbon atoms designated (i.e. C1-6 means one to six carbons). Representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
Further representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. For each of the definitions herein (e.g., alkyl, alkoxy, alkylamino, alkylthio, alkylene, haloalkyl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl), when a prefix is not included to indicate the number of carbon atoms in an alkyl portion, the alkyl moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms or 6 or fewer main chain carbon atoms. For example, C1_8 alkyl refers to a straight or branched hydrocarbon having 1, 2, 3, 4, 5 or 6 carbon atoms and includes, but are not limited to, Ci_2 alkyl, Ci_4 alkyl, C2_6 alkyl, C2_4 alkyl, Ci_6 alkyl, C2_8 alkyl, C1_7 alkyl, C2_7 alkyl and C3_6 alkyl. "Fluoro substituted alkyl" denotes an alkyl group substituted with one or more fluoro atoms, such as perfluoroalkyl, where preferably the lower alkyl is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms.
While it is understood that substitutions are attached at any available atom to produce a stable compound, when optionally substituted alkyl is an R group of a moiety such as -OR (e.g.
alkoxy), -SR (e.g. thioalkyl), -NHR (e.g. alkylamino), -C(0)NHR, and the like, substitution of the alkyl R group is such that substitution of the alkyl carbon bound to any 0, S, or N of the moiety (except where N is a heteroaryl ring atom) excludes substituents that would result in any 0, S, or N of the substituent (except where N is a heteroaryl ring atom) being bound to the alkyl carbon bound to any 0, S, or N of the moiety.
[0013] The term "alkylene" by itself or as part of another substituent means a linear or branched saturated divalent hydrocarbon moiety derived from an alkane having the number of carbon atoms indicated in the prefix. For example, (i.e., C1_6 means one to six carbons; C1_ 6 alkylene is meant to include methylene, ethylene, propylene, 2-methylpropylene, pentylene, hexylene and the like). C1_4 alkylene includes methylene -CH2-, ethylene -CH2CH2-, propylene -CH2CH2CH2-, and isopropylene -CH(CH3)CH2- , -CH2CH(CH3)-, -CH2-(CH2)2CH2-, -CH2-CH(CH3)CH2-, -CH2-C(CH3)2-, -CH2-CH2CH(CH3)- . Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer, 8 or fewer, or 6 or fewer carbon atoms being preferred in the present invention. When a prefix is not included to indicate the number of carbon atoms in an alkylene portion, the alkylene moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms, 6 or fewer main chain carbon atoms or 4 or fewer main chain carbon atoms.
[0014] "Cycloalkylalkyl" refers to an -(alkylene)-cycloalkyl group where alkylene as defined herein has the indicated number of carbon atoms or if unspecified having six or fewer, preferably four or fewer main chain carbon atoms; and cycloalkyl is as defined herein has the indicated number of carbon atoms. C3_8cycloalkyl-Ci_2alkyl means C3_8cycloalkyl-C1_ 2alkylene, wherein the cycloalkyl has 3 to 8 ring carbon atoms and the alkylene has 1 or 2 carbon atoms. Exemplary cycloalkylalkyl include, e.g., cyclopropylmethylene, cyclobutylethylene, cyclobutylmethylene, and the like.
[0015] "Cycloalkyl" by itself or as part of another substituent, refers to saturated or unsaturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-10, also 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, adamantyl, and the like. Cycloalkyl refers to hydrocarbon rings having the indicated number of ring atoms (e.g., C3_8 cycloalkyl means three to eight ring carbon atoms).
[0016] "Haloalkyl," is meant to include alkyl substituted by one to seven halogen atoms.
Haloalkyl includes monohaloalkyl and polyhaloalkyl. For example, the term "C1-6 haloalkyl"
is meant to include trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0017] "Haloalkoxy" refers to a ¨0-haloalkyl group, where haloalkyl is as defined herein, e. g., trifluoromethoxy, 2,2,2-trifluoroethoxy, difluoromethoxy, and the like.
[0018] "Alkoxy" refers to a ¨0-alkyl group, where alkyl is as defined herein.
"Cycloalkoxy" refers to a ¨0-cycloalkyl group, where cycloalkyl is as defined herein.
"Fluoro substituted alkoxy" denotes alkoxy in which the alkyl is substituted with one or more fluoro atoms, where preferably the alkoxy is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms. While it is understood that substitutions on alkoxy are attached at any available atom to produce a stable compound, substitution of alkoxy is such that 0, S, or N

(except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkoxy 0. Further, where alkoxy is described as a substituent of another moiety, the alkoxy oxygen is not bound to a carbon atom that is bound to an 0, S, or N of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety.
[0019] "Amino" or "amine" denotes the group -NH2.
[0020] "Alkylamino" refers to a ¨NH-alkyl group, where alkyl is as defined herein.
Exemplary alkylamino groups include CH3NH-, ethylamino, and the like.
[0021] "Dialkylamino" refers to a ¨N(alkyl)(alkyl) group, where each alkyl is independently as defined herein. Exemplary dialkylamino groups include dimethylamino, diethylamino, ethylmethylamino, and the like.
[0022] "Cycloalkylamino" denotes the group -NRddRee, where Rdd and Ree combine with the nitrogen to form a 5-7 membered heterocycloalkyl ring, where the heterocycloalkyl may contain an additional heteroatom within the ring, such as 0, N, or S, and may also be further substituted with alkyl, haloalkyl, haloalkoxy, alkoxy, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or R' as defined herein.
Alternatively, "cycloalkylamino" refers to a ¨NH-cycloalkyl group, where cycloalkyl is as defined herein.
[0023] "Arylamino" refers to a ¨NH-aryl group, where aryl is as defined herein.
Exemplary arylamino groups include PhNH-, naphthylamino, and the like.
[0024] "Heteroarylamino" refers to a ¨NH-heteroaryl group, where heteroaryl is as defined herein. Exemplary heteroarylamino groups include pyridinyl-NH-, pyrimidinyl-amino, and the like.
[0025] "Aryl" by itself or as part of another substituent refers to a monocyclic, bicyclic or polycyclic polyunsaturated aromatic hydrocarbon moiety containing 6 to 14 ring carbon atoms. Non-limiting examples of unsubstituted aryl groups include phenyl, 1-naphthyl, 2-naphthyl and 4-biphenyl. Exemplary aryl group, such as phenyl or naphthyl, which may be optionally fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members.
[0026] "Arylalkyl" refers to -(alkylene)-aryl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and aryl is as defined herein.

For example, aryl-Ci_2alkyl means aryl-alkylene-, where the alkylene has 1 or 2 carbon atoms. Examples of arylalkyl include benzyl, phenethyl, and the like.
[0027] "Heteroaryl" by itself or as part of another substituent refers to a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group consisting of 0, S, and N.
Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, indolyl, triazinyl, quinoxalinyl, cinnolinyl, phthalaziniyl, benzotriazinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzothienyl, quinolyl, isoquinolyl, indazolyl, pteridinyl and thiadiazolyl. "Nitrogen containing heteroaryl"
refers to heteroaryl wherein any heteroatoms are N.
[0028] "Heteroarylalkyl" refers to -(alkylene)-heteroaryl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and heteroaryl is as defined herein. . For example, heteroaryl-Ci_2alkyl means heteroaryl-alkylene-, where the alkylene has 1 or 2 carbon atoms. Examples of heteroarylalkyl include 2-pyridylmethyl, 2-thiazolylethyl, and the like.
[0029] "Heterocycloalkyl" refers to a saturated or unsaturated non-aromatic cycloalkyl group that contains from one to five heteroatoms selected from N, 0, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized, the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl. The heterocycloalkyl may be a monocyclic, a bicyclic or a polycylic ring system of 3 to 12, preferably 4 to 10 ring atoms, more preferably 5 to 8 ring atoms, even more preferably 4-6 ring atoms in which one to five ring atoms are heteroatoms selected from ¨N=, -N-, -0-, -S-, -5(0)-, or ¨S(0)2- and further wherein one or two ring atoms are optionally replaced by a -C(0)- group. The heterocycloalkyl can also be a heterocyclic alkyl ring fused with a cycloalkyl, an aryl or a heteroaryl ring. Non limiting examples of heterocycloalkyl groups include pyrrolidinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, butyrolactam moiety, valerolactam moiety, imidazolidinone moiety, hydantoin, dioxolane moiety, phthalimide moiety, piperidine, 1,4-dioxane moiety, morpholinyl, thiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-oxide, piperazinyl, pyranyl, pyridine moiety, 3-pyrrolinyl, thiopyranyl, pyrone moiety, tetrahydrofuranyl, tetrahydrothiophenyl, quinuclidinyl, and the like. A heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom.
[0030] "Heterocycloalkylalkyl" refers to -(alkylene)-heterocycloalkyl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and heterocycloalkyl is as defined herein. Examples of heterocycloalkylalkyl include 2-pyridylmethyl, 2-thiazolylethyl, and the like.
[0031] The substituents for alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, alkylene, vinyl include, but are not limited to, R', halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR', -SR', -0C(0)R', -0C(S)R', -C(0)R', -C(S)R', -C(0)OR', -C(S)OR', -S(0)R', -S(0)2R', -C(0)NHR', -C(S)NHR', -C(0)NR'R", -C(S)NR'R", -S(0)2NHR', -S(0)2NR'R", -C(NH)NHR', -C(NH)NR'R'', -NHC(0)R', -NHC(S)R', -NR"C(0)R', -NR'C(S)R", -NHS(0)2R', -NR'S(0)2R", -NHC(0)NHR', -NHC(S)NHR', -NR'C(0)NH2, -NR'C(S)NH2, -NR'C(0)NHR", -NR'C(S)NHR", -NHC(0)NR'R", -NHC(S)NR'R'', -NR'C(0)NR"R''', -NR'''C(S)NR'R", -NHS(0)2NHR', -NR'S(0)2NH2, -NR'S(0)2NHR", -NHS(0)2NR'R", -NR'S(0)2NR''R''', -NHR', and -NR'R" in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such group.
R', R" and R" each independently refer to hydrogen, C1-8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-CI-4 alkyl groups.
When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl. R', R" and R" can be further substituted with Rai, halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Ral, -Se, -0C(0)Ral, -0C(S)Ral, -C(0)Ral, -C(S)Ral, -C(0)0Ral, -C(S)OR, -S(0)Ral, -S(0)2Ral, -C(0)NHRal, -C(S)NHRal, -C(0)NRale, -C(S)NRale, -S(0)2NHRal, -S(0)2NRale, -C(NH)NHRal, -C(NH)NR Ra2, -NHC(0)Ral, -NHC(S)Ral, -NRa2C(0)Ral, -NR C(S)Ra2, -NHS(0)2Ral, -NRalS(0)2e, -NHC(0)NHRal, -NHC(S)NHRal, -NRalC(0)NH2, -NRalC(S)NH2, -NRalC(0)NHRa2, -NRalC(S)NHRa2, -NHC(0)NRale, -NHC(S)NRale, -NRalC(0)Nele, -NRa3C(S)NRale, -NHS(0)2NHRal, -NRalS(0)2NH2, -NRalS(0)2NHe, -NHS(0)2NRale, -NRalS(0)2Nele, -NHRal, and -NRale in a number ranging from zero to (2n'+1), where n' is the total number of carbon atoms in such group. Rai, Ra2 and e each independently refer to hydrogen, C1_8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups. Rai, Ra2 and e can be further substituted with Rbi, halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -ORbi, -SRbi, -0C(0)Rbi, -0C(S)Rbi, -C(0)Rbi, -C(S)Rbi, -C(0)0Rbi, -C(S)ORbi, -S(0)Rbi, -S(0)2Rbi, -C(0)NHRb1, -C(S)NHRbi, -C(0)NRbiRb2, -C(S)NRbiRb2, -S(0)2NHRbi, -S(0)2NRbiRb2, -C(NH)NHRbi, -C(NH)NRbiRb2, -NHC(0)Rbi, -NHC(S)Rbi, -NRb2C(0)Rbi , -NRb 1 C(S)Rb2, -NHS(0)2Rbi , -NRbl S(0)2Rb2, -NHC(0)NHRb1 , -NHC(S)NHRbl, -NRb1C(0)NH2, -NR' c(s)NH2, -NR'1C(0)NHRb2, -NRb1C(S)NHRb2, -NHC(0)NRblRb2, -NHC(S)NRblRb2, -NRb1C(0)NRb2Rb3, -NRb3C(S)NRblRb2, -NHS (0)2NHRbl, -NRb1S(0)2NH2, -NR11S(0)2NHRb2, -NHS (0)2NRblRb2, -NRb1S(0)2NRb2Rb3, -NHRbl, and -NRb1Rb2 in a number ranging from zero to (2p'+1), where p' is the total number of carbon atoms in such group. Rbi, Rb2 and Rb3 each independently refer to hydrogen, C1_8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups.
[0032] Substituents for the aryl and heteroaryl groups are varied and are generally selected from: R', halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR', -SR', -0C(0)R', -0C(S)R', -C(0)R', -C(S)R', -C(0)OR', -C(S)OR', -S(0)R', -S(0)2R', -C(0)NHR', -C(S)NHR', -C(0)NR'R'', -C(S)NR'R", -S(0)2NHR', -S(0)2NR'R", -C(NH)NHR', -C(NH)NR'R", -NHC(0)R', -NHC(S)R', -NR"C(0)R', -NR'C(S)R", -NHS(0)2R', -NR'S(0)2R", -NHC(0)NHR', -NHC(S)NHR', -NR'C(0)NH2, -NR'C(S)NH2, -NR'C(0)NHR'', -NR'C(S)NHR'', -NHC(0)NR'R'', -NHC(S)NR'R'', -NR'C(0)NR''R-, -NR¨C(S)NR'R", -NHS(0)2NHR', -NR'S(0)2NH25 -NR'S(0)2NHR", -NHS(0)2NR'R", -NR'S(0)2NR"R''', -NHR', -NR'R", -N35 perfluoro(Ci-C4)alkoxy, and perfluoro(Ci-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R" and R" are independently selected from hydrogen, haloalkyl, haloalkoxy, C1_8 alkyl, C3_6 cycloalkyl, cycloalkylalkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl-CI-4 alkyl, and aryloxy-C 1-4 alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms. R', R" and R" can be further substituted with Rai, halogen, -OH, -NH25 -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH25 -C(S)NH25 -S(0)2NH25 -NHC(0)NH25 -NHC(S)NH25 -NHS(0)2NH25 -C(NH)NH25 -0Ral, -SRal, -0C(0)Ral, -0C(S)Ral -C(0)Ral, -C(S)Ral, -C(0)0Ral -C(S)0Ral -S(0)Ral, -S(0)2Ral -C(0)NHRal, -C(S)NHRal -C(0)NRK
al a25 C(S)NRKal a2 5 S(0)2NHRal, -S(0)2NRal Ka2 5 C(NH)NHRal, -C(NH)NRal Ka2 NHC(0)Ral, -NHC(S)Ral, -NRa2C(0)Ral -NRal C(S)Ra2, -NHS(0)2Ral, -NRal S(0)2Ra2, -NHC(0)NHRal -NHC(S)NHRal, -NRalC(0)NH25 -NRal C(S)NH25 -NRal C(0)NHRa2, -NRal C(S)NHRa2, -NHC(0)NRal,. a25 NHC(S)NRaiRa25 -NRalC(0)NRa2 a3 5 K NRa3C(S)NRaK
l a25 NHS(0)2NHRal, -NRal S(0)2NH25 -NRalS(0)2NHRa2, -NHS(0)2NRalRa25 ----NK al S(0)2NRa2Ra3 5 NHRal 5 NRalRa2 5 5 perfluoro(Ci-C4)alkoxy, and perfluoro(Ci-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where Rai, Ra2 and e are each independently selected from hydrogen, haloalkyl, haloalkoxy, C1_8 alkyl, C3_6 cycloalkyl, cycloalkylalkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl-Ci-4 alkyl, or aryloxy-Ci-4 alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms.
[0033] When two substituents are present on adjacent atoms of a substituted aryl or a substituted heteroaryl ring, such substituents may optionally be replaced with a substituent of the formula ¨T-C(0)-(CH2)q-U-5 wherein T and U are independently -NH-5 -0-, -CH2- or a single bond, and q is an integer of from 0 to 2. Alternatively, when two substituents are present on adjacent atoms of a substituted aryl or a substituted heteroaryl ring, such substituents may optionally be replaced with a substituent of the formula -A-(CH2),-B-5 wherein A and B are independently -CH2-5 -0-, -NH-5 -S-5 -S(0)-5 -S(0)2-5 -S(0)2NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, when two substituents are present on adjacent atoms of a substituted aryl or a substituted heteroaryl ring, such substituents may optionally be replaced with a substituent of the formula -(CH2)s-X-(CH2)t-, where s and t are independently integers of from 0 to 3, and Xis -0-, -NR'-, -S-, -S(0)-, -S(0)2-, or -S(0)2NR'-. The substituent R' in -NR'- and -S(0)2NR'- is selected from hydrogen or unsubstituted C1-6 alkyl.
[0034] "Protecting group" refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G. WutS, PROTECTIVE GROUPS IN ORGANIC

CHEMISTRY, (Wiley, 4th ed. 2006), Beaucage and Iyer, Tetrahedron 48:2223-2311 (1992), and Harrison and Harrison et at., COMPENDIUM OF SYNTHETIC ORGANIC METHODS, Vols. 1-8 (John Wiley and Sons. 1971-1996). Representative amino protecting groups include formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), tri-isopropylsilyl (TIPS), phenylsulphonyl and the like (see also, Boyle, A. L.
(Editor), carbamates, amides, N-sulfonyl derivatives, groups of formula -C(0)0R, wherein R
is, for example, methyl, ethyl, t-butyl, benzyl, phenylethyl, CH2=CHCH2-, and the like, groups of the formula -C(0)R', wherein R' is, for example, methyl, phenyl, trifluoromethyl, and the like, groups of the formula -502R", wherein R" is, for example, tolyl, phenyl, trifluoromethyl, 2,2,5,7,8-pentamethylchroman-6-yl, 2,3,6-trimethy1-4-methoxyphenyl, and the like, and silanyl containing groups, such as 2-trimethylsilylethoxymethyl, t-butyldimethylsilyl, triisopropylsilyl, and the like, CURRENT PROTOCOLS IN
NUCLEIC ACID
CHEMISTRY, John Wiley and Sons, New York, Volume 1, 2000).
[0035] The term "Labile protecting group" refers to those protecting groups that are removable under mild conditions that do not significantly impact other protecting groups or the remainder of the molecule.
[0036] The term "Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy, trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, N,0-dimethylhydroxylamino, and the like.
Compounds
[0037] In one aspect, the present invention provides a compound of formula (I):
Q
0 =

I \ F
N N
iD2 (I) wherein the substituents P1, P2, L1 and Q are as defined in the Summary of the Invention. In one embodiment, P1 is H. The compounds of formula (I) are useful intermediates for the synthesis of various biologically active molecules, for example, compounds of formula (III):
Q
0 46, /,0 Y 1 \ F HN1\

N N
H (III) wherein Y is optionally substituted aryl or optionally substituted heteroaryl;
Z is optionally substituted Ci_6alkyl, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted cycloalkylamino, optionally substituted arylamino, optionally substituted heteroarylamino or NH2. Q is H or F. In one embodiment, Q is F.
[0038] In certain embodiments of compounds of formula (I), P1 can be selectively removed in the presence of the P2 group. Selective cleavage of P1 can be accomplished by adjusting the reaction conditions, such as temperature, pH, reaction time and so forth.
In some embodiments, P1 is a labile amino protecting group. Exemplary labile protecting group includes 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl. In a preferred embodiment, P1 is H.
[0039] In certain embodiments of compounds of formula (I), P2 is an amino protecting group, which is capable of forming a carbamate or an amide linkage with the amino group to which it is attached. In some embodiments, P2 is an amino protecting group selected from R3-C(0)- or R40-C(0)-, wherein R3 and R4 are each independently selected from Ci_6alkyl, aryl, heteroaryl, aryl-Ci_2alkyl, heteroaryl-Ci_2alkyl, C3_10cycloalkyl, C3_10cycloalkyl-C1_ 2alkyl, ethynyl or vinyl, each of which is optionally substituted. In certain instances, R3 and R4 are each independently selected from Ci_6alkyl, aryl, heteroaryl, aryl-Ci_2alkyl, heteroaryl-Ci_2alkyl, C3_10cycloalkyl, C3_10cycloalkyl-Ci_2alkyl, ethynyl or vinyl, each of which is optionally substituted with 1-3 Ra groups independently selected from halogen, Ci_6alkyl, Ci-6haloalkyl, Ci_6haloalkoxy, fluoro substituted Ci_6alkyl, fluoro substituted Ci_6alkoxy, aryl, heteroaryl, Ci_6alkoxy, -CN, -NO2, -OH, Ci_6alkyl-OC(0)-, Ci_6alkyl-C(0)0- or -SiMe3, wherein the aliphatic or aromatic portion of Ra is further optionally substituted with from 1-3 Rb groups independently selected from halogen, Ci_6alkyl, Ci_6alkoxy, -CN, -NO2 or -OH. In other instances, R3 and R4 are each independently methyl, ethyl, phenyl, 2,2,2-trichloroethyl, (CH3)2CHCC-, 2-trimethylsilylethyl, 1-methyl-l-phenylethyl, cyclobutyl, cyclopropyl, allyl, vinyl, 1-adamantyl, benzyl or diphenylmethyl, each of which is optionally substituted with from 1-3 Ra groups. In some embodiments, Ra is F, Cl, Br, I, -CH3, Phenyl, t-butyl, Me0-, -NO2, -CN, -CF3, CF30-, -OH or -CH=CH2. In one embodiment, P2 is 2,6-dichlorophenylcarbonyl. In another embodiment, P2 is 2,5-dichlorophenylcarbonyl, 2,3-dichlorophenylcarbonyl or 2,4-dichlorophenylcarbonyl. In certain embodiments, P2 is phenylcarbonyl optionally substituted with from 1-2 groups independently selected from F, Cl, Br, CN or NO2. In some embodiments of compounds of formula (I), P2 is H.
All the other variables L1, P1 and Q are as defined in any of the embodiments described herein.
[0040] In some embodiments of compounds of formula (I), L1 is Br, Cl, I, tosy1-0-, mesyl-0-, trifluoromethanesulfony1-0-, R1-S020- or R2C(0)0, wherein R1 and R2 are each independently selected from aryl, aryl-Ci_4alkyl or Ci_6alkyl, each of which is optionally substituted with from 1-3 Rc substituents selected from halogen, -CH=CH2, -CN, -OH, -NH2, -NO2, -C(0)0H, -C(0)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -ORd, -SR', -0C(0)Rd, -C(0)Rd, -C(0)OR', -C(S)OR', -S(0)Rd, -S(0)2R', -C(0)NHRd, -C(0)NRdRd, -S(0)2NHRd, -S(0)2NRdRd, -C(NH)NHRd, -C(NH)NRdRd, -NHC(0)Rd, -NRdC(0)Rd, -NHS(0)2R', -NRdS(0)2Rd, -NHC(0)NHRd, -NHRd or -NRdRd, wherein each Rd is independently selected from Ci_6alkyl or aryl. In some instances, Rd is -CH3, ethyl or phenyl. In some embodiments, L1 is Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. In one embodiment, L1 is Br or Cl.
All the other variables, P1, P2 and Q are as defined in any of the embodiments described herein.
[0041] In one embodiment of compounds of formula (I), P1 is H; and Q is F. In another embodiment, P1 and Q are H. In yet another embodiment, P1 is H; L1 is Br or Cl; and Q is F.
In a preferred embodiment of compounds of formula (I), L1 is Br or Cl; P1 is H; and P2 is 2,6-dichlorophenylcarbonyl.
Methods
[0042] In another aspect, the present invention provide a method for preparing a compound of formulas (I) and (Ia). The method comprises contacting/reacting a compound of formula (II):
Q
0 =

i =-=, \ F NH2 I
N N
H (II) with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
Q
0 46, , ,....... , F NH2 I
N N
iD2 (Ia); and contacting/reacting a compound of formula (Ia) with an agent of the formula:
P1-X3 under conditions sufficient to form the compound of formula (I). Alternatively, compound of formula (I) can also be prepared by first reacting a compound of formula (II) with an agent of the formula: P1-X3 to form an intermediate product, followed by reacting the intermediate product with an agent of the formula: P2-X1. X1 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. X3 is a leaving group. In one embodiment, X3 is Cl, Br, I, tosy1-0-, mesy1-0, CF3S(0)20-, CF3C(0)0- or CH3C(0)0-. P1 is a labile protecting group. In one embodiment, P1 is 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl. In one embodiment, P2 is H. In another embodiment, P2 is an amino protecting group as found in T.W. Greene and P.G.
Wuts, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, (Wiley, 4th ed. 2006) or as defined in any of the embodiments described herein. Q is H or F. L1 is Br, Cl, I, R1-S020- or R2C(0)0, wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl. In some embodiments, R1 and R2 are each independently selected from aryl, aryl-Ci_4alkyl or C1-6alkyl, each of which is optionally substituted with from 1-3 Rc substituents, wherein each Rd is independently selected from Ci_6alkyl or aryl. In some instances, Rd is ¨CH3, ethyl or phenyl. In some embodiments, L1 is Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0-or CH3C(0)0-. In a preferred embodiment, L1 is Br or Cl.
[0043] In some embodiments, the reactions for preparing compounds of formulas (I) or (Ia) can be carried out in the presence of a base dissolved in an organic solvent.
Some preferred bases include dimethylaminopyridine (DMAP), triethylamine (TEA), N,N-diisopropylethylamine (DIPEA) and combinations thereof DMAP is generally present in a catalytic amount of about 0.05, 0.07, 0.08, 0.1, 0.2, 0.3, 0.4 or 0.5 equivalents. TEA or DIPEA can range from about 1-5 equivalents, for example, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents. The organic solvents used include, but are not limiting to, tetrahydrofuran (THF), 2-methyl-THF, acetonitrile, dichloromethane and benzene. A preferred solvent is 2-methyl-THF. The solvents can be present in various volumes, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 12 volumes.
[0044] Compounds of formula (II) can be prepared by contacting a compound of formula (V):
Q
0 =

I \ F NO2 N N
H (V) with a reducing agent under conditions sufficient to form the compounds of formula (II). The variables, L1 and Q are as defined in any of the embodiments described herein.
In one embodiment, L1 is Br and Q is F. The reducing agent may be, but is not limited to, tin chloride dihydrate (SnC12=2H20). Typically, 1-5 equivalents (e.g., 1, 2, 3, 4 or 5 eqs) of the reducing agent are used. The reaction can be carried out at a temperature of about 40-90 C, preferably about 50-70 C, more preferably about 60 C. The solvents for the reaction can be 2-methyl-THF or a mixture of 1:1 ethyl acetate/THF. The volumes of the solvents can be from about 5 to 100 or about 7 to 80. In one embodiment, a compound of formula (V) is treated with 3 or 4 equivalents of SnC12 in 80 volumes of 1;1 ethyl acetate/THF or 7 volumes of 2-methyl THF at 60 C.
[0045] Compounds of formula (V) can be prepared by reacting a compound of formula (VI):

F
NO2 (VI) with a compound of formula (VII):

N.---- N
I-1 (VII) in the presence of a metal halide, such as A1C13 under conditions sufficient to form the compounds of formula (V). X2 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. The variables, L1 and Q
are as defined in any of the embodiments described herein. In a preferred embodiment, X2 is Br or Cl. In one embodiment, Q is F, L1 is Br and X2 is Cl. The solvents used in the reaction include, but are not limited to, CH3NO2, acetonitrile, dichloromethane, dichloroethane, benzene, toluene and combinations thereof. In one embodiment, the solvent is dichloroethane.
[0046] In another aspect, the present invention provides a method for preparing a compound of formula (III):
Q

I, Y 1 \ \ F H N1\

N N
H (III).
In one embodiment, the method comprises coupling, sulfonylation and deprotection steps.
For example, the method comprises:
(i) contacting a compound of formulas (I)or (Ia) with an agent of the formula : Y-B(0R5)2 (i.e., formula IVb) or the formula :Y-Sn(Bu)3 (i.e., formula IVc) and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IV):
Q
0 *
Y
\ F NHP1 I
N N
\
p2 (IV);
(ii) reacting a compound of formula (IV) with an agent of the formula: A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (IX):

Q
0 =//0 Y
1 \ \ F HN1\

N N
\
p2 (IX); and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III).
[0047] Alternatively, the compounds of formula (III) can be prepared by carrying out sulfonylation reaction first, followed by Suzuki coupling and removing of the protecting group P2. For example, the method comprises:
(i) contacting a compound of formula (I) with an agent of the formula: A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (VIM:
Q
0 .0 1 \ F HN1\

N N
\
p2 (VIII);
(ii) reacting a compound of formula (VIII) with an agent of the formula (IVb):
Y-B(0R5)2 or formula (IVc): Y-Sn(Bu)3 and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IX); and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III), wherein:
Q is H or F;
P1 and P2 are as defined in any of the embodiments as described herein;
R5 is ¨OH, Ci_6alkyl or two ¨0R5 substituents together with the boron atom to which they are attached form an optionally substituted 5 or 6-membered ring;
A1 is a leaving group;
Y is optionally substituted aryl or optionally substituted heteroaryl; and Z is ¨N(R6)(R7) or ¨C(R8)(R9)(R10); wherein:
R6 and R7 are each independently selected from the group consisting of H, optionally substituted Ci_6alkyl, optionally substituted C3_8cycloalkyl, optionally substituted C3_8cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, 0 or S, wherein the four to eight-membered ring is optionally substituted; and R8, R9 and R1 are each independently H, optionally substituted Ci_6alkyl, optionally substituted, Ci_6haloalkyl, optionally substituted Ci_6haloalkoxy, optionally substituted C3_8cycloalkyl, optionally substituted C3_ 8cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or -X2R11, wherein X2 is -NR12, 0 or S; R12 is H, Ci_6alkyl or aryl; and R11 is H, Ci_6alkyl, Ci_6haloalkyl, Ci_6haloalkoxy, C3_8cycloalkyl, C3_ 8cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R11 is optionally substituted with from 1 to 3 Re substituents selected from halogen, -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Rf, -SRf, -0C(0)R, -0C(S)R, -C(0)R, -C(S)R, -C(0)OR, -C(S)OR, -S(0)R, -S(0)2R, -C(0)NHRf, -C(S)NHRf, -C(0)NRfRf, -C(S)NRfRf, -S(0)2NHRf, -S(0)2NRfRf, -C(NH)NHRf, -C(NH)NRfRf, -NHC(0)Rf, -NHC(S)Rf, -NRfC(0)Rf, -NRfC(S)Rf, -NHS(0)2R, -NRfS(0)2Rf, -NHC(0)NHRf, -NHC(S)NHRf, -NRfC(0)NH2, -NRfC(S)NH2, -NRfC(0)NHRf, -NRfC(S)NHRf, -NHC(0)NRfRf, -NHC(S)NRfRf, -NRfC(0)NRfRf, -NRfC(S)NRfRf, -NHS(0)2NHRf, -NRfS(0)2NH2, -NRfS(0)2NHRf, -NHS(0)2NRfRf, -NRfS(0)2NRfRf , -NHRf, -NRfRf and Rf, wherein Rf is Ci-6alkyl, C3_6cycloalkyl, heterocycloalkyl, heteroaryl or aryl, wherein Rf is optionally substituted with from 1-3 Rg substituents selected from -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR", -SR", -0C(0)Rh, -0C(S)Rh, -C(0)Rh, -C(S)R", -C(0)OR", -C(S)OR", -S(0)Rh, -S(0)2R", -C(0)NHRh or Rh, wherein Rh is Ci_6alkyl; or any two of the R8, R9 and R1 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, 0 or S. In some instances, at each occurrence, at least two of the R8, R9 and R1 groups are not simultaneously hydrogen. In one embodiment, Q is F. In another embodiment, Q is H. In yet another embodiment, Y is 4-chlorophenyl; Z is propyl; Q is F; R5 is -OH; P1 is H; and P2 is 2,6-dichlorophenylcarbonyl.
[0048] The agents Y-B(0R5)2 (i.e., formula IVb) or Y-Sn(Bu)3 (i.e., formula IVc) are either commercially available or can be readily prepared in accordance with the procedures described in the literature. In some embodiments, -B(0R5)2 is:
2-....< 2 ________ 0-\
-I3 ,µ -131\ y -B(01-)2 13`
, O'c , 0 r 0 In one embodiment, Y-B(0R5)2 is Y-B(OH)2. Y is as defined in any of the embodiments as described herein.
[0049] The agent A1-S(0)2-Z (i.e., formula IVa) is either commercially available or can be readily prepared in accordance with the procedures described in the literature. The leaving group A1 can be Cl, Br, I, tosy1-0-, mesy1-0, CF3S(0)20-, CF3C(0)0- or CH3C(0)0-. In one embodiment, A1 is Cl.
[0050] In some embodiments of compounds of formula (III), Y is selected from phenyl, 2-pyridyl, 3-pyridyl, 4-pyridy1,2-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 1-pyrazolyl, 2-pyrazolyl, 3-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazoly1 or 5-isothiazolyl, each of which is optionally substituted with from 1-3 Re groups; or 1-3 Rf groups; or 1-3 Rg groups; or 1-3 Rh groups. In certain instances, Re is F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, ethyl, CH30, Et0-, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino, 1-hydroxy-1-methylethyl, methylcarbamoyl, 1-carboxycyclopropyl, 1-carbamoylcyclopropyl, 1-methoxycarbonylcyclopropyl, 1-cyanoisopropyl, 1-hydroxycyclopropyl, 1-hydoxyisopropyl, cyclobutoxy, cyclopentoxy, cyclohexyloxy, 4-morpholino, 4-hydroxypiperidiny1,1- piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, azetidinyl, pyrrolidinyl, cyclopropylcarbamoyl, 5-methy1-1,2,4-oxadiazol-3-yl, 5-methyl-1,3,4-oxadiazol-2y1, 5-dimethylamino-1,3,4-oxadiazol-2y1 or 5-methylamino-1,3,4-thiadiazol-2-yl. The other variables Q and Z are as defined in any of the embodiments as described herein.
[0051] In some embodiments of compounds of formula (III), Y is phenyl, 1-naphthyl or 2-naphthyl, each of which is optionally substituted with from 1-3 substituents selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino or 1-hydroxy-l-methylethyl or methylcarbamoyl. The other variables Q and Z are as defined in any of the embodiments as described herein.
[0052] In some embodiments of compounds of formula (III), Y is selected from 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2- thiophenyl, 3-thiophenyl, 2-amino-quinazolin-5-yl, 2-amino-quinazolin-6-yl, 2-amino-quinazolin-6-yl, 2-amino-quinazolin-7-yl, 2-amino-quinazolin-8-yl, 2-oxo-6-indolinyl, 2-oxo-4-indolinyl, 2-oxo-5-indolinyl, 2-oxo-7-indolinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 1H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-y1 or 1H-indazol-7-yl, each of which is substituted with from 1 to 2 substituents independently selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, C2H50-, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, 1-carboxycyclopropyl, 1-carbamoylcyclopropyl, 1-methoxycarbonylcyclopropyl, 1-cyanoisopropyl, 1-hydroxycyclopropyl, 1-hydoxyisopropyl, cyclobutoxy, cyclopentoxy, cyclohexyloxy, 4-morpholino, 4-hydroxypiperidiny1,1- piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, azetidinyl, pyrrolidinyl, cyclopropylcarbamoyl, 5-methy1-1,2,4-oxadiazol-3-yl, 5-methyl-1,3,4-oxadiazol-2y1, 5-dimethylamino-1,3,4-oxadiazol-2y1, 5-methylamino-1,3,4-thiadiazol-2-yl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, isopropyl, 1-pyrrolidinyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino or 1-hydroxy-l-methylethyl. In certain instances, Y is 4-chlorophenyl. In other instances, Y is 4-pyrimidinyl or 5-pyrimidinyl, each of which optionally substituted with from 1, 2, or 3 substituents independently selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, 1-cyanocyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, isopropyl, 1-pyrrolidinyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino or 1-hydroxy-1-methylethyl. The other variables Q and Z are as defined in any of the embodiments as described herein.
[0053] In some embodiments of compounds of formula (III), Z is 1-azetindinyl, pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl, 3-oxazolidinyl, 3-thiazolidinyl, 2-isoxazolidinyl, 2-isothiazolidinyl, 1-pyrazolidinyl, 1-piperazinyl, 1-hexahydropyrimidinyl or 1-hexahydropyridazinyl, each of which is optionally substituted with from 1-3 Re groups.
In certain instances, Re is F, CH3, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. The other variables Q and Y are as defined in any of the embodiments as described herein.
[0054] In some embodiments of compounds of formula (III), Z is selected from 1-azetindinyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl, 3-oxazolidinyl, 3-thiazolidinyl, 2-isoxazolidinyl, 2-isothiazolidinyl, 1-pyrazolidinyl, 1-piperazinyl, 1-hexahydropyrimidinyl or 1-hexahydropyridazinyl, each of which is optionally substituted with from 1-2 R' substituents selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-oxetanyl, 3-oxetanyl, 2-oxetanylmethyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 4-morpholinyl, 2-morpholinyl or 3- morpholinyl. In certain instances, R' is F, CH3, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. The other variables Q
and Y
are as defined in any of the embodiments as described herein.
[0055] In some embodiments of compounds of formula (III), Z is Ci_6alkyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cycloheptyl or cyclooctyl, each of which is optionally substituted with from 1-3 RJ groups selected from F, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-oxetanyl, 3-oxtetanyl, 2-oxetanylmethyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 4-morpholinyl, 2-morpholinyl or 3-morpholinyl. In one embodiment, Z is propyl. The other variables Q and Y are as defined in any of the embodiments as described herein.
[0056] In some embodiments of compounds of formula (III), Z is selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl, 1-azetindinyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl 3-oxazolidinyl, 3-thiazolidinyl, 2-isoxazolidinyl, 2-isothiazolidinyl, 1-pyrazolidinyl, 1-piperazinyl, 1-hexahydropyrimidinyl, 1-hexahydropyridazinyl, (CH3)(CF3CH2)N-, cycloproyplmethylamino, sec-butyl, pentan-2-y1 and pentan-3-yl, each of which is optionally substituted with from 1-2 R" groups selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-oxetanyl, 3-oxtetanyl, 2-oxetanylmethyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 4-morpholinyl, 2-morpholinyl or 3- morpholinyl. In one instance, Rk is -F, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. In another instance, Rk is -F, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH- or CH3(C0)(CH3)N-. In yet another instance, Rk is vinyl or propen-3-yl. The other variables Q and Y are as defined in any of the embodiments as described herein.
[0057] Various palladium or nickel complexes can be used for the preparation of compounds of formula (III). Preferably, palladium phosphine complexes are used in the reaction. The palladium complexes include, but are not limited to, Pd(PPh3)4, PdC12(PPh3)2, bis[1,2-bis(diphenylphosphino)ethane]palladium, bis(tri-t-butylphosphine)palladium, diacetobis(triphenylphosphine)palladium, tris(dibenzylideneacetone)dipalladium (Pd2(dba)2), Pd(OAc)2, dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II), and dichloro[1,1'-bis(di-i-propyl-phosphino)ferrocene]palladium (II). In one embodiment, the palladium complex is PdC12(PPh3)2. The palladium complexes can be present between 0.01 and 0.1 equivalents, e.g., about 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09 or 0.1 equivalents. Exemplary nickel complexes include, but are not limited to, NiC12(dppf), bis(tricyclohexylphosphine) nickel(II) chloride (NiC12(PCy3)2) and NiC12(PPh3)2.
[0058] The Suzuki coupling reaction can be carried out in various solvents, including, but not limiting to, toluene, dioxane, THF, 2-methyl-THF, water or a mixture thereof In one embodiment, the reaction is carried out in dioxane or 2-methyl-THF. The reaction can be performed at a temperature between 50-100 C, 60-90 C or 70-85 C. In one embodiment, the reaction is carried out using 0.025-0.05 eq of PdC12(PPh3)2, 2-3 eq of K2CO3 or NaHCO3, 1 eq of compound of formula (I), 1.5-2 eq of compound of formula (IVb), 10 volumes of dioxane and 5 volumes of water.
[0059] The sulfonylation reaction can be carried out in various solvents including, but not limiting to, pyridine, dichloromethane, THF, acetonitrile, toluene, dioxane, 2-methyl-THF or a mixture thereof Excess solvents can be used during the reaction, for example, the solvents can be from 1-5 equivalents, such as 1, 1.5, 2, 2.5, 3, or 4 equivalents. The temperature for the reaction can be maintained from about 50-110 C, e.g., 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105 or 110 C. In one embodiment, the reaction is carried out in a mixed solvents of pyridine and 10 volumes of dioxane at about 100 C.
[0060] The deprotection reaction can be conducted by reacting a compound of formula (IX) with NH3 dissolved in an organic solvent at a temperature from about 50-110 C, e.g., 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105 or 110 C. The solvents used include, but are not limited to, methanol (Me0H), ethanol (Et0H), dimethylformamide (DMF), dimethylacetamide (DMA), THF, dimethylsulfoxide (DMSO), dioxane, isopropanol (IPA) or combinations thereof In one embodiment, the reaction can be conducted at 55 C in the presence of NH3 (5 eq), Me0H (5 eq, 10 volumes) and DMA (5 volumes). In another embodiment, the reaction can be conducted at 100 C in the presence of THF (5 volumes) and NH3/IPA (12 eq).
Examples
[0061] The following examples are offered to illustrate, but not to limit the claimed invention.
[0062] Certain molecules claimed in this patent can exist in different enantiomeric and diastereomeric forms and all such variants of these compounds are claimed.
[0063] Those skilled in the art will also recognize that during standard work up procedures in organic chemistry, acids and bases are frequently used. Salts of the parent compounds are sometimes produced, if they possess the necessary intrinsic acidity or basicity, during the experimental procedures described within this patent.
Example 1: Preparation of (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-y1)-(2,6-dffluoro-3-nitro-phenyl)methanone (3) Scheme 1 Br F
0 .CI 40 1 N.-.--N
H Br ,..
F AlC13 1 --,.... \ F NO2 CH2Cl2 2 NO2 N " 3 H
[0064] To an 50-liter flask was added 1,2-dichloroethane (DCE, 20 L), followed by 5-bromoazaindole (1) (2 kg, 10.152 mol) to result an orange slurry. Aluminum Chloride (5.421 kg, 40.608 mol) was slowly added to the flask. The first 1.5 kg of the addition was exothermic resulting a dark solution. The rest of the A1C13 was added to give a reaction mixture. To the reaction mixture was added 2,6-difluoro-3-nitrobenzoyl chloride 2 (2.25 kg, 10.125 mol) via an addition funnel over a period of 1.5 h. During the addition, the reaction temperature was maintained at or below 45 C. After the addition, the reaction mixture was stirred at 50 C overnight, cooled to room temperature (-22 C) and transferred into two separate 20 L flasks. Water (25 L) and acetonitrile (12 L) were added to a 50-liter flask and cooled to 0 C. The reaction mixture was quenched by adding water/acetonitrile solution while keeping the temperature at or below 40 C. The mixture obtained was filtered, and the filtrate was washed with acetonitrile:water (1:1, 2x4 L), water (4 L) and acetonitrile (4 L), followed by drying in vacuum. Compound 3 (2.948 kg, 73.4% yield) was obtained.
MS
(ESI): M-411 = 382.9 and 383.9. 1H NMR (DMSO-d6, 6 ppm): 7.55 (1 H, m), 8.47 (2 H, m), 8.53 (1 H, d, J=2.2 Hz), 8.65 (1H, d, J = 2.2Hz), 13.25 (1 H, s).

Example 2: Preparation of (3-amino-2,6-difluoro-phenyl)-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (4) Scheme 2.
F
F
.
0 .

SnCl2 Br Br F NH2 1 `,, \ F NO2 2-methyl-THF I
N ,,, I ,,, N " 4 " 3 H
H
[0065] A 50-liter flask was added 2-methyl-tetrahydrofuran (2-methyl-THF) (36 L), compound 3 (2.85 kg, 7.455 mol) and tin(II) chloride (5.03 kg, 22.365 mol).
The mixture was heated to 60 C. Upon completion, the reaction was quenched with an aqueous potassium carbonate solution (20%). The resulting mixture was filtered with celite and the solid residue was washed with 2-methyl-THF and tetrahydrofuran (THF). The filtrate was washed with an aqueous NaC1 solution (15 L,10%) and the organic layer was separated. The organic layer was further washed with an aqueous NaC1 solution (15 L, 20%) and concentrated on a rotovap to yield compound 4 (2.536 kg, 96.65% yield). MS
(ESI): M+H ' =
353 and 354. iti NMR (DMS0- d6, 6 ppm): 5.22(2 H, s), 6.93 (2 H, m), 8.12(1 H, s), 8.47 (1 H, d J=2.3 Hz), 8.54 (1 H, d J-1.6 Hz), 13.2 (1 H, s).
Example 3: Preparation of (3-amino-2,6-difluoro-phenyl)-[5-bromo-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (5) Scheme 3.
F
F 0 .
0 ilt 2,6-dichlorobenzoyl chloride Br \ F NH2 Br , I
\ F NH2 õ, triethylamine, 2-methyl-THF N " Cl N N

Cl P---=
[0066] Compound 4 (2.5 kg, 7.114 mol) obtained from Example 2 was added into a 50-liter flask and cooled to 9.3 C. To compound 4 in the 50-liter flask was added triethylamine (0.864 kg, 8.537 mol), followed by 4-dimethylaminopyridine (DMAP) (0.087 kg, 0.7114 mol) and 2,6-dichlorobenzoyl chloride (1.34 kg, 6.40 mol) in 2-methyl-THF (25 L) over a period of 2 hrs. The reaction was quenched with methanol (0.30 L at room temperature and added an aqueous NaC1 solution (12.5 L, 15%) and celite (0.5 kg). The mixture was stirred and filtered through celite. The filtrate was concentrated and added 5 volumes of heptanes.
The resulting solution was stirred for about 1 hr and dried with sodium sulfate (1 kg) and filtered. Compound 5 was isolated by removing the solvents under vacuum (3.47 kg, 92.93%
yield). MS (ESI): M+FI1 = 524, 525.8, 527.8. 1H NMR (DMSO-d6, 6 ppm): 5.36 (2 H, s), 7.01 (2 H, m), 7.68 (3 H, s), 8.34 (1H, brs), 8.61 (1 H, brs), 8.72 (1 H, d J=2.3 Hz).
Example 4: Preparation of (3-amino-2,6-difluoro-phenyl)45-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (7) Scheme 4.
F F
0 . CI
to 0 PdC12(PPI13)2 / NaHCO3 CI 0 =
Br \ I F
NH2 ___________________________________________ . NH2 CI \ I
, 2-Me-THF / water / reflux FCI
IN
N B N N
0 104 HOõOH
[0067] Under a nitrogen atmosphere, a 50-liter flask is charged with compound 5 (1.735 kg, 3.304 mol) prepared from Example 3 in 2-methyl-THF, boronic acid 6 (0.877 kg, 5.617 mol), PdC12(PPh3)2 (0.116 kg, 0.165 mol) and an aqueous sodium bicarbonate (0.833 kg, 9.912 mol) solution (8.7 L). The reaction mixture is degassed and heated to reflux for 7 hrs and stirred at room temperature overnight. Compound 6 (129.0 g) and PdC12(PPh3)2 (6.6 g) are added again and the reaction mixture is heated to reflux for another 5 hrs. Celite (1.735 kg) is added and the mixture is stirred for 30 minutes and then filtered through a pad of celite.
The residue is washed with 2-methyl-THF. The organic layer is separated, washed with a 10% NaC1 aqueous solution (4 L) for three times, further washed with a 20%
NaC1 aqueous solution, filtered, and dried over Na2504. The filtrate is concentrated by removing about 80-85% of solvent, added ethyl acetate (3.5 L) and stirred overnight. The mixture is filtered and washed with ethyl acetate (2x3.5 L) twice. Compound 7, is isolated after removing the solvents and drying at 45 C for 48 hrs (2.765 kg, 74% yield).

Example 5: Preparation of N4345-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (9) Scheme 5.
F
41), F

Or Pyridine CI
_,... 0 lik ,-.... \ F NH2 k I + \ F
Dioxane N'S CI CI' '0 I
ci N N reflux N N
0 ip, 8 CI CI
[0068] To a compound 7 (2.76 kg, 4.961 mol) in dioxane (25 L) is added pyridine (3.92 kg, 49.6 mol), followed by compound 8 (2.42 kg, 16.99 mol). The reaction mixture is heated to reflux and stirred overnight. The dioxane solvent is removed by distillation and the reaction is quenched by adding a mixture of ethyl acetate (16 L) and water (14 L). The reaction mixture is filtered and the filtrate is separated into an organic and an aqueous layer. The organic layer is washed with a 10% NaC1 aqueous solution (20 L) followed by a 20% NaC1 aqueous solution (20 L). The organic layer is separated, stirred in the presence of activated carbon (350 g) and filtered through celite. Compound 9 is isolated by removing the solvents under vacuum (1.81 kg, 52% yield).
Example 6: Preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (10) Scheme 6.
F F

CI el 0 441t 0 0 0 4t 7N NH3 / Me0H N." S
I \ F
N N ___________________ .

H
[0069] To a high pressure vessel is added compound 9 (1.70 kg, 2.567 mol) in THF (5 L), followed by an ammonia/isopropyl alcohol solution (30.80 mol of ammonia in 12 L of isopropyl alcohol). The mixture is heated to 100 C overnight. When the reaction is completed, the solvents are removed in vacuum and the residue is dissolved in isopropanol.

Compound 10 is isolated and further purified by recrystallization using a mixture of THF (7 L) and isopropanol (14 L). Yield: 0.763 kg (60.7%).
Example 7: Preparation of (3-amino-2,6-difluoro-phenyl)45-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (7) Scheme 7.
0 NH2 is NH2 F
Br F I 0 I . F F
, 0 , \ , 0 N C
C B(OH)2 N CI v.-(Ph3P)2PdC12 N N CI
0 40 NaHCO3 2-MeTHF/Water CI
[0070] Compound 5 (900g; 1.7 mol) compound 6 (375.8g; 1.4 mol), sodium bicarbonate (302.6g; 2.1 mol) followed by 3-methyl-THF (9 L) and water (4.5 L) were added to the 20L
reactor and the mixture was purged with nitrogen at least for lh. Bis-triphenylphospino-palladium (II) chloride (60.8g; 0.086 mol) was added and the reaction mixture was heated to 70-75 C and stirred for 2h. The reaction mixture was cooled and filtered over celite pad.
The organic layer of the filtrate was separated, washed with water, and concentrated under vacuum. The precipitated solid was isolated by filtration and dried to provide compound 7 (953.9g) as a brown solid (Purity= 95.1%; Yield = ¨100%). 1H NMR (DMSO-d6): 6 (ppm) 8.75-8.76 (d, J = 2.2 Hz, 1H), 8.59 (m, 1H), 8.52 (s, 1H), 7.80-7.82 (d, J=8.6 Hz, 1H), 7.69-7.71 (m, 3H), 7.54-7.56 (d, J = 8.6 Hz, 2H), 6.99-7.07 (m, 2H), and 5.36 (s, 2H). MS (ESI) [M+H]1 = 556.1 and 558.1.

Example 8: Preparation of N4345-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (9) Scheme 8.

A
2 L., a 0 a 0 401 0, b N N CI ________ a- N N CI
Pyridine / DMAP
o Si 15-20 C o Si CI CI
[0071] Compound 7 (800g; 1.44 mol) and dimethylamino pyridine (7.2g; 0.059 mol), under nitrogen, were added to a 5L three-necked-round bottom flask cooled in an ice water bath.
Anhydrous pyridine (1.8L) was charged and the mixture was stirred at 10-15 C
until a homogeneous solution was obtained. Propane-l-sulfonyl chloride (308g; 2.16 mol) was added drop-wise from an addition funnel while keeping the reaction temperature <20 C and the reaction mixture was stirred at 20-25 C for 3h. The reaction mixture was added to a mixture of 2-methyl-THF (7L) and water (10L) in a flask and the organic layer was separated, washed with 1N HC1 (2L) followed by brine (2L), and dried. The residue was azeotroped with toluene to remove the residual water to provide crude compound 9 (1116.4g) which was used in the next step without purification.
Example 9: Preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (10).
Scheme 9.
H
0 N,Is ei o"b H
CI N s F F I
CI el lel o"b N N CI
NH3 /Me0H I I 0 THF

CI
[0072] Crude compound 9 and THF (6L) were added to a 12L round-bottom flask and stirred until the clear solution was obtained. A solution of ammonia in methanol (1.24L; 7M) was added and stirred for 24h at 28-35 C. The reaction mixture was concentrated to near dryness after with methanol was added and concentrated at 45-50 C. The separated solid was filtered and dried at 45-50 C under vacuum to obtain crude compound 10 (601.7g; Purity = > 95%;
Yield = 85.4%). Recrystallization of the crude in acetone/methanol (2:1) provided compound in 74% yield with a purity of 98.5%. 1H NMR (DMSO-d6):6 (ppm) 9.78 (s, 1H), 8.72-8.73 (d, J=2.2 Hz, 1H), 8.65 (brs, 1H), 8.26 (s, 1H), 7.79-7.82 (d, J = 8.5 Hz, 2H), 7.57-7.61 (m, 3H), 7.28-7.32 (t, J = 8.3 Hz, 1H), 2.50-2.52 (m, 2H), 1.73-1.78 (m, 2H), and 0.96-0.98 (t, 3H). MS (ESI) [M+H'] ' = 490.1 and 492.1.
[0073] All patents, patent applications and other references cited in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains, and are incorporated by reference in their entireties, including any tables and figures, to the same extent as if each reference had been incorporated by reference in its entirety individually.
[0074] One skilled in the art would readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims
[0075] While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention
[0076] In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
[0077] Also, unless indicated to the contrary, where various numerical values are provided for embodiments, additional embodiments are described by taking any two different values as the endpoints of a range. Such ranges are also within the scope of the described invention.

Claims (20)

WHAT IS CLAIMED IS:
1. A compound of formula (I):
wherein:
Q is F or H;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group or hydrogen; and L1 is Br, Cl, I, R1-SO2O- or R2C(O)O; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
2. The compound of claim 1, wherein P1 is -H.
3. The compound of claim 1, wherein P1 is selectively cleaved in the presence of P2.
4. The compound of claim 3, wherein P1 is 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl.
5. The compound of any of claims 1-4, wherein P2 is an amino protecting group selected from R3-C(O)- or R4O-C(O)-, wherein R3 and R4 are each independently selected from C1-6alkyl, aryl, heteroaryl, aryl-C1-2alkyl, heteroaryl-C1-2alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-2alkyl, ethynyl or vinyl, each of which is optionally substituted.
6. The compound of claim 5, wherein P2 is -H.
7. The compound of claim 5, wherein P2 is 2,6-dichlorophenylcarbonyl.
8. The compound of any of claims 5, wherein R3 or R4 is optionally substituted with 1-3 Ra groups independently selected from halogen, C1-6alkyl, fluoro substituted C1-6alkyl, fluoro substituted C1-6alkoxy, aryl, heteroaryl, C1-6alkoxy, -CN, -NO2, -OH, C1-6alkyl-OC(O)-, C1-6alkyl-C(O)O- or -SiMe3, wherein the aliphatic or aromatic portion of R a is further optionally substituted with from 1-3 R b groups independently selected from halogen, C1-6alkyl, C1-6alkoxy, -CN, -NO2 or -OH.
9. The compound of claim 8, wherein R a is F, Cl, Br, I, -CH3, Phenyl, t-butyl, MeO-, -NO2, -CN, -CF3, CF3O-, -OH or -CH=CH2.
10. The compound of any of claims 1-9, wherein R3 and R4 are each independently methyl, ethyl, phenyl, 2,2,2-trichloroethyl, (CH3)2CHC.ident.C-, 2-trimethylsilylethyl, 1-methyl-1-phenylethyl, cyclobutyl, cyclopropyl, allyl, vinyl, 1-adamantyl, benzyl or diphenylmethyl, each of which is optionally substituted with from 1-3 R a groups.
11. The compound of any of claims 1-10, wherein L1 is Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, R1-SO2O- or R2C(O)O, wherein R1 and R2 are each independently selected from aryl, aryl-C1-4alkyl or C1-6alkyl, each of which is optionally substituted with from 1-3 R c substituents selected from halogen, -CH=CH2, -CN, -OH, -NH2, -NO2, -C(O)OH, -C(O)NH2, -S(O)2NH2, -NHC(O)NH2, -NHC(S)NH2, -NHS(O)2NH2, -C(NH)NH2, -OR d, -SR d, -OC(O)R d, -C(O)R d, -C(O)OR d, -C(S)OR d, -S(O)R d, -S(O)2R d, -C(O)NHR d, -C(O)NR d R d, -S(O)2NHR d, -S(O)2NR d R d, -C(NH)NHR d, -C(NH)NR d R d, -NHC(O)R d, -NR d C(O)R d, -NHS(O)2R d, -NR d S(O)2R d, -NHC(O)NHR d, -NHR d or -NR d R d, wherein each R
d is independently selected from C1-6alkyl or aryl.
12. The compound of claim 11, wherein L1 is Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-.
13. The compound of claim 1, wherein P1 is H; P2 is 2,6-dichlorophenylcarbonyl; and L1 is Br.
14. The compound of claim 1, wherein P1 is H; P2 is H; and L1 is Br.
15. A method for preparing a compound of formula (Ia), said method comprising:
contacting a compound of formula (II):
with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):

wherein:
X1 is selected from Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-;
P2 is an amino protecting group;
Q is H or F; and L1 is Br, Cl, I, R1-SO2O- or R2C(O)O-; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
16. A method for preparing a compound of formula (I) said method comprising:
contacting a compound of formula (II):
with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
reacting a compound of formula (Ia) with an agent of formula: P1-X3 under conditions sufficient to form the compound of formula (I);

wherein:
X1 is selected from Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-;
X3 is a leaving group;
P1 is a labile protecting group;
P2 is an amino protecting group;
Q is H or F;
L1 is Br, Cl, I, R1-SO2O- or R2C(O)O; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
17. The method of claim 15, wherein said contacting is carried out in the presence of triethylamine and 4-dimethylaminopyridine.
18. The method of claim 15 or 16, wherein L1 is Br.
19. The method of claim 15 or 16, wherein P2 is 2,6-dichlorophenyl; and L1 is Br.
20. The method of claim 15 or 16, wherein Q is F.
CA2874555A 2012-05-31 2013-05-30 Synthesis of pyrrolo [2, 3 - b] pyridines Active CA2874555C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261653994P 2012-05-31 2012-05-31
US61/653,994 2012-05-31
US13/793,917 2013-03-11
US13/793,917 US9150570B2 (en) 2012-05-31 2013-03-11 Synthesis of heterocyclic compounds
PCT/US2013/043400 WO2013181415A1 (en) 2012-05-31 2013-05-30 Synthesis of pyrrolo [2, 3 - b] pyridines

Publications (2)

Publication Number Publication Date
CA2874555A1 true CA2874555A1 (en) 2013-12-05
CA2874555C CA2874555C (en) 2019-04-02

Family

ID=48577959

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874555A Active CA2874555C (en) 2012-05-31 2013-05-30 Synthesis of pyrrolo [2, 3 - b] pyridines

Country Status (25)

Country Link
US (2) US9150570B2 (en)
EP (1) EP2861591B1 (en)
JP (1) JP6258301B2 (en)
KR (1) KR102078429B1 (en)
CN (2) CN104507937A (en)
AR (1) AR091159A1 (en)
AU (1) AU2013267325B2 (en)
BR (1) BR112014029454B1 (en)
CA (1) CA2874555C (en)
CL (1) CL2014003228A1 (en)
CR (1) CR20140576A (en)
EA (1) EA027928B1 (en)
EC (1) ECSP14033037A (en)
ES (1) ES2687300T3 (en)
HK (1) HK1206010A1 (en)
IL (1) IL235819B (en)
MX (1) MX2014014465A (en)
MY (1) MY168935A (en)
NZ (1) NZ630453A (en)
PE (1) PE20142335A1 (en)
PH (1) PH12014502613B1 (en)
SG (1) SG11201407851RA (en)
TW (1) TWI603970B (en)
UY (1) UY34825A (en)
WO (1) WO2013181415A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI404719B (en) 2009-04-03 2013-08-11 Hoffmann La Roche Compositions and uses thereof
KR101821768B1 (en) 2009-11-05 2018-01-24 리젠 파마슈티컬스 소시에떼 아노님 Novel benzopyran kinase modulators
CN106220623A (en) 2009-11-06 2016-12-14 普莱希科公司 Compounds and methods for and indication thereof for kinases regulation
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
AU2010336524B2 (en) 2009-12-23 2015-10-08 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI510487B (en) 2010-04-21 2015-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012158957A2 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
TWI601725B (en) * 2012-08-27 2017-10-11 加拓科學公司 Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PT2935248T (en) 2012-12-21 2018-04-05 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2014145051A1 (en) 2013-03-15 2014-09-18 Jiazhong Zhang Heterocyclic compounds and uses thereof
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
KR20160013028A (en) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 Compounds for kinase modulation, and indications therefor
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774177T3 (en) 2014-09-15 2020-07-17 Plexxikon Inc Heterocyclic compounds and uses of these
WO2016083956A1 (en) 2014-11-29 2016-06-02 Shilpa Medicare Limited Substantially pure vemurafenib and its salts
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HUE047657T2 (en) 2015-05-06 2020-05-28 Plexxikon Inc Synthesis of 1h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases
JP6946194B2 (en) 2015-05-06 2021-10-06 プレキシコン インコーポレーテッドPlexxikon Inc. Solid form of compounds that regulate kinases
WO2016191295A1 (en) * 2015-05-22 2016-12-01 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN108137585B (en) 2015-09-21 2021-10-22 普莱希科公司 Heterocyclic compounds and their use
BR112018011475A2 (en) 2015-12-07 2018-12-04 Plexxikon Inc compounds and methods for kinase modulation and indication for kinase
WO2017161045A1 (en) 2016-03-16 2017-09-21 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
CA3056777A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
KR102051625B1 (en) * 2017-06-30 2019-12-02 주식회사 엘지화학 Novel hetero-cyclic compound and organic light emitting device comprising the same
CA3070505C (en) 2017-07-25 2023-09-26 Plexxikon Inc. Formulations of a compound modulating kinases
WO2019075243A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases
AU2018354423A1 (en) 2017-10-27 2020-05-14 Plexxikon Inc. Formulations of a compound modulating kinases
JP2021518367A (en) 2018-03-20 2021-08-02 プレキシコン インコーポレーテッドPlexxikon Inc. Compounds and methods for IDO and TDO regulation, and signs for them
CA3136224A1 (en) 2019-04-09 2020-10-15 Plexxikon Inc. Condensed azines for ep300 or cbp modulation and indications therefor
WO2021216898A1 (en) 2020-04-23 2021-10-28 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
CN116322690A (en) 2020-08-21 2023-06-23 奥普纳生物有限公司 Combination pharmaceutical anticancer therapies
US11578971B2 (en) 2021-02-12 2023-02-14 Holloway Ndt & Engineering Inc. Ultrasonic testing using a phased array

Family Cites Families (302)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB145299A (en) 1919-08-14 1920-07-02 Carl Theodor Thorssell Improvements in or relating to apparatus for the production of nitrogen products
US2234705A (en) 1940-04-12 1941-03-11 Eastman Kodak Co Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids
US2413258A (en) 1942-07-07 1946-12-24 United Gas Improvement Co Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters
CH513136A (en) 1966-10-21 1971-09-30 Minnesota Mining & Mfg Perfluoroalkylsulphonamides antimicrobial antiparasitic pesticidal pla - nt growth regulatory and pharmacological agents
IL46853A0 (en) 1974-03-20 1975-05-22 Bayer Ag Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
CA1148562A (en) * 1979-02-22 1983-06-21 Alfred J. Bird Catalyst for the hydrogenation of halogen substituted aromatic nitro compounds
US4301159A (en) 1980-06-20 1981-11-17 Shionogi & Co., Ltd. N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives
AU547405B2 (en) 1981-07-08 1985-10-17 Sanofi Amidobenzamides
US4664504A (en) 1983-01-20 1987-05-12 Tokyo Shibaura Denki Kabushiki Kaisha Image forming apparatus
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
AU567140B2 (en) 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
ATE56096T1 (en) 1984-03-15 1990-09-15 Immunex Corp TEST FOR INSTANT DETECTION OF LIGANDS, TEST KIT AND ITS PREPARATION.
IT1196133B (en) 1984-06-06 1988-11-10 Ausonia Farma Srl FURANIC DERIVATIVES WITH ANTI-ULCER ACTIVITY
US4714693A (en) 1986-04-03 1987-12-22 Uop Inc. Method of making a catalyst composition comprising uniform size metal components on carrier
DE3642315A1 (en) 1986-12-11 1988-06-23 Boehringer Mannheim Gmbh NEW PYRROLOBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
US5688655A (en) 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5658775A (en) 1988-05-17 1997-08-19 Sloan-Kettering Institute For Cancer Research Double copy retroviral vector
JP2528706B2 (en) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 Pharmaceutical composition of dihydropyridine compound
JP3082204B2 (en) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ Recombinant retrovirus with an amphotropic and ecotropic host range
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
FR2649979B1 (en) * 1989-07-20 1992-01-17 Rhone Poulenc Chimie PROCESS FOR HYDROGENATION OF HALOGENO NITROAROMATIC DERIVATIVES IN THE PRESENCE OF A SULFUR DERIVATIVE
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
DE4022414A1 (en) 1990-07-13 1992-01-16 Bayer Ag SUBSTITUTED PYRROLO-PYRIDINE
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
DK0580860T4 (en) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Process for preparing a solid dispersion
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5632957A (en) 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
GB9127531D0 (en) 1991-12-31 1992-02-19 Fujisawa Pharmaceutical Co Heterocyclic compound
FR2687402B1 (en) 1992-02-14 1995-06-30 Lipha NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
JPH05236997A (en) 1992-02-28 1993-09-17 Hitachi Ltd Chip for catching polynucleotide
JPH06135946A (en) 1992-10-30 1994-05-17 Otsuka Pharmaceut Co Ltd Pyrazine derivative
AU686115B2 (en) 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
CN1118598A (en) 1993-03-01 1996-03-13 默克·夏普-道姆公司 Pyrrolo-pyridine derivatives
EP0687267B1 (en) 1993-03-01 1999-09-01 MERCK SHARP &amp; DOHME LTD. Pyrrolo-pyridine derivatives as ligands of dopamine receptor
ES2134929T3 (en) 1993-03-01 1999-10-16 Merck Sharp & Dohme PIRROLO-PIRIDINA DERIVATIVES AS LINKS FOR DOPAMINE RECEPTORS.
US5576319A (en) 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
JP3394777B2 (en) 1993-05-27 2003-04-07 セレクタイド コーポレーション Topologically separated, encoded solid-phase library
US5840485A (en) 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
IT1265057B1 (en) 1993-08-05 1996-10-28 Dompe Spa TROPIL 7-AZAINDOLIL-3-CARBOXYAMIDE
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6468742B2 (en) 1993-11-01 2002-10-22 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5965452A (en) 1996-07-09 1999-10-12 Nanogen, Inc. Multiplexed active biologic array
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5360882A (en) 1994-02-04 1994-11-01 Isp Investments Inc. Eutectic compositions of divinyl imidazolidone and vinyl caprolactam
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US5763198A (en) 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
GB9416162D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
WO1996005200A1 (en) 1994-08-10 1996-02-22 Merck Sharp & Dohme Limited TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO[2,3-b]PYRIDINE
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5837815A (en) 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
GB9503400D0 (en) 1995-02-21 1995-04-12 Merck Sharp & Dohme Therpeutic agents
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
GB9507291D0 (en) 1995-04-07 1995-05-31 Merck Sharp & Dohme Therapeutic agents
GB2299581A (en) 1995-04-07 1996-10-09 Merck Sharp & Dohme 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5866411A (en) 1995-09-08 1999-02-02 Pedersen; Finn Skou Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
US5747276A (en) 1995-09-15 1998-05-05 The Scripps Research Institute Screening methods for the identification of novel antibiotics
WO1997016533A1 (en) 1995-10-31 1997-05-09 The Regents Of The University Of California Mammalian artificial chromosomes and methods of using same
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5908401A (en) 1996-05-08 1999-06-01 The Aps Organization, Llp Method for iontophoretic delivery of antiviral agents
US5725838A (en) 1996-05-31 1998-03-10 Resolution Pharmaceuticals, Inc. Radiolabeled D4 receptor ligands
AU3568897A (en) 1996-06-07 1998-01-05 Eos Biotechnology, Inc. Immobilised linear oligonucleotide arrays
CN1077892C (en) 1996-06-25 2002-01-16 武田药品工业株式会社 Oxazolone derivatives and their use as anti-helicobacter pylori agents
KR100576148B1 (en) 1996-08-12 2006-05-03 미쯔비시 웰 파마 가부시키가이샤 Medicines Comprising Rho Kinase Inhibitor
JPH10130269A (en) 1996-09-04 1998-05-19 Nippon Chemiphar Co Ltd Carboline derivative
JPH1087629A (en) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd New isoquinoline derivative, and its medicinal use
AU734841B2 (en) 1996-11-19 2001-06-21 Amgen, Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
JP2001514506A (en) 1997-03-07 2001-09-11 トロピックス・インコーポレーテッド Protease inhibitor analysis
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
SG72827A1 (en) 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
AU8096798A (en) 1997-06-27 1999-01-19 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6826296B2 (en) 1997-07-25 2004-11-30 Affymetrix, Inc. Method and system for providing a probe array chip design database
PT901786E (en) 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
US6161776A (en) 1997-08-12 2000-12-19 Nibco Inc. Multi-layered, porous mat turf irrigation apparatus and method
AU8908198A (en) 1997-08-15 1999-03-08 Hyseq, Inc. Methods and compositions for detection or quantification of nucleic acid species
ES2225407T3 (en) 1997-09-11 2005-03-16 Bioventures, Inc. METHOD FOR PRODUCING ORDERLY HIGH DENSITY PROVISIONS.
US6178384B1 (en) 1997-09-29 2001-01-23 The Trustees Of Columbia University In The City Of New York Method and apparatus for selecting a molecule based on conformational free energy
US6465178B2 (en) 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
CZ299156B6 (en) 1997-12-22 2008-05-07 Bayer Corporation Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use
CA2300197A1 (en) 1997-12-23 1999-07-01 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
WO1999051595A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1067931A1 (en) 1998-04-02 2001-01-17 Merck &amp; Co., Inc. (a New Jersey corp.) Antagonists of gonadotropin releasing hormone
AU3117899A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2326143A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002510685A (en) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド Gonadotropin-releasing hormone antagonist
EP1071423A1 (en) 1998-04-02 2001-01-31 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
IL138668A0 (en) 1998-04-03 2001-10-31 Phylos Inc Addressable protein arrays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
JP3720264B2 (en) 1998-08-17 2005-11-24 千寿製薬株式会社 Glaucoma prevention / treatment agent
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
AU763758B2 (en) 1998-08-28 2003-07-31 Astrazeneca Ab Novel compounds
US6594527B2 (en) 1998-09-18 2003-07-15 Nexmed Holdings, Inc. Electrical stimulation apparatus and method
ID28362A (en) 1998-09-18 2001-05-17 Basf Ag 4-AMINOPIROLOPIRIMIDINA AS A CINNAMER INVOLVEMENT
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6277628B1 (en) 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
IT1303759B1 (en) 1998-11-17 2001-02-23 Dompe Spa IMPROVED PROCEDURE FOR THE PREPARATION OF 7-AZAINDOLYL-3-CARBOXYLIC ACID.
US6277489B1 (en) 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
US20010001449A1 (en) 1998-12-30 2001-05-24 Thomas R. Kiliany Low-pressure hydrocracking process
KR20020009570A (en) 1999-03-05 2002-02-01 도리이 신이찌로 HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE α4β2 RECEPTOR
US6792306B2 (en) 2000-03-10 2004-09-14 Biophoretic Therapeutic Systems, Llc Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
HUP0105114A3 (en) 1999-03-17 2002-09-30 Astrazeneca Ab Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation
AR028475A1 (en) 1999-04-22 2003-05-14 Wyeth Corp DERIVATIVES OF AZAINDOL AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION.
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US6221653B1 (en) 1999-04-27 2001-04-24 Agilent Technologies, Inc. Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
FR2793793B1 (en) 1999-05-19 2004-02-27 Adir NOVEL SUBSTITUTED DIMERIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
CA2375734A1 (en) 1999-06-03 2000-12-14 Knoll Gmbh Benzothiazinone and benzoxazinone compounds
WO2001009121A2 (en) 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones_as tyrosine kinase inhibitors
US6653151B2 (en) 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
WO2001024236A1 (en) 1999-09-27 2001-04-05 Infineon Technologies North America Corp. Semiconductor structures having a capacitor and manufacturing methods
GB9924962D0 (en) 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
US20010008765A1 (en) 1999-12-06 2001-07-19 Fuji Photo Film Co., Ltd. DNA chip and reactive solid carrier
AR029423A1 (en) 1999-12-21 2003-06-25 Sugen Inc COMPOSITE DERIVED FROM PIRROLO- [PIRIMIDIN OR PIRIDIN] -6-ONA, METHOD OF PREPARATION OF THESE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A METHOD FOR REGULATING, MODULATING OR INHIBITING THE ACTIVITY OF THE PROTEIN QUINASA AND ONE METHOD MAMMALS DISEASE
EP1255536B1 (en) 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
FR2805259B1 (en) 2000-02-17 2002-03-29 Inst Nat Sante Rech Med NOVEL N-MERCAPTOACYL AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
JP2001278886A (en) 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd Benzoxazine derivative and medicament containing the same
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
CA2413510C (en) 2000-06-26 2007-12-11 Lilly Icos Llc Condensed pyrazindione derivatives
JP4068958B2 (en) 2000-06-26 2008-03-26 ファイザー・プロダクツ・インク Pyrrolo (2,3-D) pyrimidine compounds as immunosuppressants
WO2002018346A1 (en) 2000-08-31 2002-03-07 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
US6618625B2 (en) 2000-11-29 2003-09-09 Leon M. Silverstone Method and apparatus for treatment of viral diseases
DE60206889T2 (en) 2001-02-27 2006-07-27 Astrazeneca Ab PHARMACEUTICAL FORMULATION CONTAINING BICALUTAMIDE
EP1378247B1 (en) 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002085896A1 (en) 2001-04-24 2002-10-31 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
GB0114417D0 (en) 2001-06-13 2001-08-08 Boc Group Plc Lubricating systems for regenerative vacuum pumps
EP1267111A1 (en) 2001-06-15 2002-12-18 Dsm N.V. Pressurized fluid conduit
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
SE0102300D0 (en) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
SE0102439D0 (en) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
US6858860B2 (en) 2001-07-24 2005-02-22 Seiko Epson Corporation Apparatus and method for measuring natural period of liquid
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
JP2003073357A (en) 2001-09-03 2003-03-12 Mitsubishi Pharma Corp Rho KINASE INHIBITOR COMPRISING AMIDE COMPOUND
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
EP1452525A4 (en) 2001-10-30 2005-01-26 Nippon Shinyaku Co Ltd Amide derivatives and drugs
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
KR100669578B1 (en) 2002-01-22 2007-01-15 워너-램버트 캄파니 엘엘씨 2-PYRIDIN-2-YLAMINO-PYRIDO[2,3-d]PYRIMIDIN-7-ONES
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US6884889B2 (en) 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
KR20040111445A (en) 2002-03-28 2004-12-31 에자이 가부시키가이샤 7-Azaindoles as Inhibitors of c-Jun N-terminal Kinase for The Treatment of Neurodegenerative Disorders
ATE457312T1 (en) 2002-03-28 2010-02-15 Eisai R&D Man Co Ltd AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES
EP1495016A2 (en) 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
AU2003247959B2 (en) 2002-07-09 2010-07-29 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6878887B2 (en) 2002-08-07 2005-04-12 Matsushita Electric Industrial Co., Ltd. Anti-malfunction mechanism for variable output device
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
SE0202463D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
CN102516417B (en) 2002-09-06 2014-12-10 天蓝制药公司 Cyclodextrin-based polymers for therapeutics delivery
US20040142864A1 (en) 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
US6766199B2 (en) 2002-10-10 2004-07-20 Proventure (Far East), Limited Skin/hair treatment method and system
US7183241B2 (en) 2002-10-15 2007-02-27 Exxonmobil Research And Engineering Company Long life lubricating oil composition with very low phosphorus content
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
SE0203654D0 (en) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
CA2509711A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
SE0300119D0 (en) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (en) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US8486447B2 (en) 2003-02-03 2013-07-16 Novartis Ag Pharmaceutical formulation
MXPA05008441A (en) 2003-02-14 2005-10-19 Wyeth Corp Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands.
SE0300456D0 (en) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
JP2007524374A (en) 2003-02-28 2007-08-30 プレキシコン,インコーポレーテッド PYK2 crystal structure and use
WO2004078756A2 (en) 2003-03-06 2004-09-16 Eisai Co., Ltd. Jnk inhibitors
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
EP1648889B1 (en) 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
CL2004001884A1 (en) 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
AR045595A1 (en) 2003-09-04 2005-11-02 Vertex Pharma USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20060281803A1 (en) 2003-09-23 2006-12-14 Lindsley Craig W Pyrazole modulators of metabotropic glutamate receptors
KR100793095B1 (en) 2003-10-01 2008-01-10 주식회사 프로메디텍 Novel Sulfone Amide Derivatives Capable Of Inhibiting BACE
US7449582B2 (en) 2003-10-08 2008-11-11 Irm Llc Compounds and compositions as protein kinase inhibitors
DE10357510A1 (en) 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroaryl-substituted benzenes
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
AU2004312215B2 (en) 2003-12-24 2009-03-05 Dupont Nutrition Biosciences Aps Proteins
WO2005080393A1 (en) 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
JP2007527918A (en) 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Therapeutic modulation of PPAR gamma activity
KR20050091462A (en) 2004-03-12 2005-09-15 한국과학기술연구원 Furopyrimidine compound and ddr2 tyrosine kinase activity inhibitor comprising the same
CN103554104A (en) 2004-03-30 2014-02-05 沃泰克斯药物股份有限公司 Azaindoles useful as inhibitors of jak and other protein kinases
CA2561724A1 (en) 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
JP4842929B2 (en) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク Pyrrolopyrimidine derivatives useful for cancer treatment
WO2005115374A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for therapeutic use
EP1755597A2 (en) 2004-06-17 2007-02-28 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1761520B1 (en) * 2004-06-23 2008-07-09 Eli Lilly And Company Kinase inhibitors
EP2325184A1 (en) 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
US7140816B2 (en) 2004-07-20 2006-11-28 H&S Tool, Inc. Multi-functional tube milling head
WO2006015124A2 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
KR20070053237A (en) 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 Pyrrolo-pyridine kinase modulators
US20060024361A1 (en) 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
EP1789393A2 (en) 2004-07-30 2007-05-30 GPC Biotech AG Pyridinylamines
WO2006063167A1 (en) 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
CA2605738C (en) 2005-04-25 2013-10-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel azaheterocyclic compounds as kinase inhibitors
FR2884821B1 (en) 2005-04-26 2007-07-06 Aventis Pharma Sa SUBSTITUTED PYRROLOPYRIDINES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
WO2007013896A2 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
CA2605764A1 (en) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Amorphous cinacalcet hydrochloride and preparation thereof
US8067638B2 (en) 2005-06-21 2011-11-29 Mitsui Chemicals, Inc. Amide derivative and insecticide containing the same
HUE027370T2 (en) * 2005-06-22 2016-10-28 Plexxikon Inc Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
DE102005034406A1 (en) 2005-07-22 2007-02-01 Ratiopharm Gmbh New salts of rosiglitazone
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007109604A2 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US7963673B2 (en) 2006-05-30 2011-06-21 Finn Bruce L Versatile illumination system
DK2848610T3 (en) 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Inhibitors of kinase activity
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
GB0624084D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (en) * 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
JP2010526848A (en) 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー Pharmaceutical composition for poorly soluble drugs
CL2008001540A1 (en) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compounds derived from pyrrolopyridines and pyrazolopyridines; pharmaceutical composition; and use in the treatment of cancer.
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CA2691752C (en) 2007-07-23 2016-01-26 Evangelos Karavas Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
JP2009077712A (en) 2007-09-11 2009-04-16 F Hoffmann La Roche Ag DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-Raf KINASE INHIBITOR
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
WO2009111277A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
CN102149712A (en) 2008-02-29 2011-08-10 阵列生物制药公司 Pyrazole [3, 4-b] pyridine Raf inhibitors
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2009115084A2 (en) 2008-03-20 2009-09-24 Schebo Biotech Ag Novel pyrrolopyrimidine derivatives and the use thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PE20091846A1 (en) 2008-05-19 2009-12-16 Plexxikon Inc PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS
US8110576B2 (en) * 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
JP5767965B2 (en) * 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドPlexxikon Inc. 5H-pyrrolo [2,3-B] pyrazine derivatives that regulate kinases and indications thereof
RU2493157C2 (en) 2008-08-20 2013-09-20 Пфайзер Инк. PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
AR074199A1 (en) 2008-11-20 2010-12-29 Glaxosmithkline Llc COMPOSITE OF 6- (4-PYRIMIDINYL) -1H-INDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR DECREASE OF CANCER GRAVITY.
EP2406259A1 (en) * 2009-03-11 2012-01-18 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases
TW201036972A (en) 2009-03-11 2010-10-16 Plexxikon Inc Compounds and uses thereof
TWI404719B (en) 2009-04-03 2013-08-11 Hoffmann La Roche Compositions and uses thereof
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013503189A (en) * 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド RAF inhibitory compounds and methods of use thereof
CN106220623A (en) 2009-11-06 2016-12-14 普莱希科公司 Compounds and methods for and indication thereof for kinases regulation
WO2011060216A1 (en) * 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2501236B1 (en) * 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
AU2010336524B2 (en) * 2009-12-23 2015-10-08 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI510487B (en) 2010-04-21 2015-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2964757B1 (en) 2010-09-09 2013-04-05 Giroptic OPTICAL DEVICE FOR CAPTURING IMAGES ACCORDING TO A 360 ° FIELD
EP2616467A1 (en) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2012109075A1 (en) * 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (en) 2011-02-21 2013-09-18 Plexxikon Inc SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC
WO2012138809A1 (en) 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
WO2012158957A2 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
KR20160013028A (en) * 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 Compounds for kinase modulation, and indications therefor
ES2774177T3 (en) 2014-09-15 2020-07-17 Plexxikon Inc Heterocyclic compounds and uses of these

Also Published As

Publication number Publication date
EP2861591B1 (en) 2018-07-11
SG11201407851RA (en) 2014-12-30
US20140094611A1 (en) 2014-04-03
AU2013267325A1 (en) 2015-01-15
TWI603970B (en) 2017-11-01
US9695169B2 (en) 2017-07-04
CR20140576A (en) 2015-01-30
MX2014014465A (en) 2015-02-12
JP6258301B2 (en) 2018-01-10
IL235819A0 (en) 2015-02-01
WO2013181415A1 (en) 2013-12-05
US9150570B2 (en) 2015-10-06
CA2874555C (en) 2019-04-02
KR20150021070A (en) 2015-02-27
JP2015518051A (en) 2015-06-25
TW201406754A (en) 2014-02-16
ES2687300T3 (en) 2018-10-24
ECSP14033037A (en) 2015-12-31
AR091159A1 (en) 2015-01-14
AU2013267325B2 (en) 2017-11-02
UY34825A (en) 2013-12-31
BR112014029454A2 (en) 2017-06-27
KR102078429B1 (en) 2020-02-17
IL235819B (en) 2019-10-31
HK1206010A1 (en) 2015-12-31
EA027928B1 (en) 2017-09-29
PH12014502613A1 (en) 2015-01-21
NZ630453A (en) 2017-02-24
EA201492165A1 (en) 2015-05-29
PE20142335A1 (en) 2015-01-10
CN104507937A (en) 2015-04-08
BR112014029454B1 (en) 2022-03-22
PH12014502613B1 (en) 2015-01-21
MY168935A (en) 2019-01-10
CN109608450A (en) 2019-04-12
CL2014003228A1 (en) 2015-02-27
US20150368243A1 (en) 2015-12-24
EP2861591A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
CA2874555C (en) Synthesis of pyrrolo [2, 3 - b] pyridines
CA2986920C (en) Synthesis of heterocyclic compounds
WO2020118683A1 (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
AU2023270260A1 (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
EP4249077A1 (en) Novel acridinium salt and method for producing same
Won et al. Chan–Lam coupling reaction of sulfamoyl azides with arylboronic acids for synthesis of unsymmetrical N-arylsulfamides
CA3134902A1 (en) Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
Xu et al. An improved synthesis of 2-oxa-7-azaspiro [3, 5] nonane and analogs as novel reagents in medicinal chemistry
CN115996727A (en) Process for preparing Rho related protein kinase inhibitors and intermediates in the process
UA113984C2 (en) INTERMEDIATE COMPOUNDS IN PYROLINE SYNTHESIS [2,3-b]
CN106458947A (en) Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
WO2018153820A1 (en) Process for the preparation of chiral pyrollidine-2-yl- methanol derivatives